Axogen Inc
$ 43.00
1.51%
12 Jun - close price
- Market Cap 2,286,647,000 USD
- Current Price $ 43.00
- High / Low $ 43.54 / 41.53
- Stock P/E N/A
- Book Value 4.61
- EPS -0.64
- Next Earning Report 2026-08-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.02 %
- ROE -0.18 %
- 52 Week High 45.83
- 52 Week Low 9.22
About
AxoGen, Inc., develops and markets surgical solutions for physical damage or transection of peripheral nerves. The company is headquartered in Alachua, Florida.
Analyst Target Price
$50.78
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-28 | 2026-02-24 | 2025-10-29 | 2025-08-05 | 2025-05-08 | 2025-02-25 | 2024-11-07 | 2024-08-08 | 2024-05-02 | 2024-03-05 | 2023-11-07 | 2023-08-07 |
| Reported EPS | 0.07 | 0.07 | 0.12 | 0.12 | -0.02 | 0.07 | 0.07 | 0.05 | -0.06 | -0.06 | 0.01 | -0.03 |
| Estimated EPS | 0.0714 | 0.0586 | 0.07 | 0.06 | 0.016 | 0.03 | 0.01 | -0.04 | -0.07 | -0.1 | -0.06 | -0.13 |
| Surprise | -0.0014 | 0.0114 | 0.05 | 0.06 | -0.036 | 0.04 | 0.06 | 0.09 | 0.01 | 0.04 | 0.07 | 0.1 |
| Surprise Percentage | -1.9608% | 19.4539% | 71.4286% | 100% | -225% | 133.3333% | 600% | 225% | 14.2857% | 40% | 116.6667% | 76.9231% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-04 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.04 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | Jan 1970 | |
|---|---|---|
| Payment Date | None | None |
| Amount | $1.0 | $0.06 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AXGN
2026-06-09 02:39:33
Axogen (AXGN) has seen a 35.1% share price gain over the past three months, despite reporting net losses. While a popular narrative suggests the stock is 18.4% undervalued with a fair value of $50.78 based on future growth, its current Price/Sales ratio of 9.3x is significantly higher than industry averages, indicating potential valuation risk. Investors are advised to consider both the potential rewards from accelerating revenue and the risks, such as reliance on its Avance Nerve Graft and regulatory setbacks, before making investment decisions.
2026-06-07 13:08:52
This article analyzes market sentiment around Axogen, Inc. (NASDAQ:AXGN), a company that is currently unprofitable. It aims to determine whether investors are anticipating future growth or are concerned about its current financial state.
2026-06-06 12:40:20
Wall Street Zen downgraded AxoGen (NASDAQ:AXGN) from a "buy" to a "hold" rating, though most other analysts maintain a "buy" rating with a consensus target price of $46.50. The company reported mixed Q1 earnings, missing EPS expectations but exceeding revenue forecasts, while also showing negative net margin and return on equity. Insider selling and significant institutional ownership were also noted in the report.
2026-06-03 21:39:11
This article provides a financial overview of AxoGen Inc (AXGN), detailing its revenue composition, profitability margins, and a comparison with competitors. AXGN exhibits a strong gross margin of 75.16% but reports negative operating and net margins, as well as a negative Return on Equity. The company is benchmarked against peers like XRAY and ESTA, highlighting its competitive gross margin.
2026-06-02 20:36:00
This article analyzes Axogen Inc. (NASDAQ: AXGN) using AI models to identify technical signals and institutional trading strategies. It highlights a weak near- and mid-term sentiment but a strong long-term outlook, with specific entry, target, and stop-loss zones for position trading, momentum breakouts, and risk hedging. The analysis also provides multi-timeframe signal strengths and support/resistance levels for the stock.
2026-05-23 01:09:13
Lisanti Capital Growth LLC has made a new $3.57 million investment in AxoGen, Inc. ($AXGN), purchasing 109,175 shares. This investment positions AxoGen with approximately 80.29% institutional ownership and follows mostly positive analyst ratings, leading to a "Moderate Buy" consensus. Despite a mixed Q4 earnings report with missed EPS but topped revenue estimates, the stock is trading near its 12-month high.
